X4 Pharmaceuticals (XFOR) EV to EBITDA (2019 - 2026)

X4 Pharmaceuticals (XFOR) has reported EV to EBITDA for 8 consecutive years, with 24.09 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EV to EBITDA fell 2723.02% year-over-year to 24.09; the trailing twelve-month figure through Jun 2026 stood at 4.49 (down 2074.32% YoY), and the FY2025 full-year result was 0.55, up 128.78% from the prior year.
• EV to EBITDA fell to 24.09 in Q2 2026 per XFOR's latest filing, from 15.0 in the prior quarter.
• Across five years, EV to EBITDA topped out at 46.98 in Q2 2024 and bottomed at 365.54 in Q2 2023.
• Historically, EV to EBITDA has averaged 78.27 across 5 years, with a median of 32.7 in 2026.
• The sharpest annual moves came in 2025 and 2026: EV to EBITDA surged 203.51% in 2025, then plunged 17681.53% in 2026.
• Over 5 years, EV to EBITDA stood at 69.23 in 2022, then slumped by 150.7% to 173.56 in 2023, then surged by 98.88% to 1.95 in 2024, then soared by 203.51% to 2.02 in 2025, then tumbled by 1292.65% to 24.09 in 2026.
• According to Business Quant data, EV to EBITDA over the past three periods registered 24.09, 15.0, and 2.02 for Q2 2026, Q1 2026, and Q4 2025 respectively.